235 related articles for article (PubMed ID: 16757690)
1. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS).
Teachey DT; Obzut DA; Axsom K; Choi JK; Goldsmith KC; Hall J; Hulitt J; Manno CS; Maris JM; Rhodin N; Sullivan KE; Brown VI; Grupp SA
Blood; 2006 Sep; 108(6):1965-71. PubMed ID: 16757690
[TBL] [Abstract][Full Text] [Related]
2. Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome.
Janić MD; Brasanac CD; Janković JS; Dokmanović BL; Krstovski RN; Kraguljac Kurtović JN
Pediatr Blood Cancer; 2009 Dec; 53(6):1117-9. PubMed ID: 19588524
[TBL] [Abstract][Full Text] [Related]
3. Targeting Notch signaling in autoimmune and lymphoproliferative disease.
Teachey DT; Seif AE; Brown VI; Bruno M; Bunte RM; Chang YJ; Choi JK; Fish JD; Hall J; Reid GS; Ryan T; Sheen C; Zweidler-McKay P; Grupp SA
Blood; 2008 Jan; 111(2):705-14. PubMed ID: 17925488
[TBL] [Abstract][Full Text] [Related]
4. Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS).
Dowdell KC; Pesnicak L; Hoffmann V; Steadman K; Remaley AT; Cohen JI; Straus SE; Rao VK
Exp Hematol; 2009 Apr; 37(4):487-94. PubMed ID: 19217201
[TBL] [Abstract][Full Text] [Related]
5. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
Sneller MC; Wang J; Dale JK; Strober W; Middelton LA; Choi Y; Fleisher TA; Lim MS; Jaffe ES; Puck JM; Lenardo MJ; Straus SE
Blood; 1997 Feb; 89(4):1341-8. PubMed ID: 9028957
[TBL] [Abstract][Full Text] [Related]
6. Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome.
Rao VK; Dowdell KC; Dale JK; Dugan F; Pesnicak L; Bi LL; Hoffmann V; Penzak S; Avila NA; Fleisher TA; Puck JM; Straus SE
Am J Hematol; 2007 Dec; 82(12):1049-55. PubMed ID: 17674358
[TBL] [Abstract][Full Text] [Related]
7. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS).
Teachey DT; Manno CS; Axsom KM; Andrews T; Choi JK; Greenbaum BH; McMann JM; Sullivan KE; Travis SF; Grupp SA
Blood; 2005 Mar; 105(6):2443-8. PubMed ID: 15542578
[TBL] [Abstract][Full Text] [Related]
8. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome.
Rao VK; Dugan F; Dale JK; Davis J; Tretler J; Hurley JK; Fleisher T; Puck J; Straus SE
Br J Haematol; 2005 May; 129(4):534-8. PubMed ID: 15877736
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil as an alternate immunosuppressor for autoimmune lymphoproliferative syndrome.
Kossiva L; Theodoridou M; Mostrou G; Vrachnou E; Le Deist F; Rieux-Laucat F; Kanariou MG
J Pediatr Hematol Oncol; 2006 Dec; 28(12):824-6. PubMed ID: 17164652
[TBL] [Abstract][Full Text] [Related]
10. Use of Sirolimus (Rapamycin) for Treatment of Cytopenias and Lymphoproliferation Linked to Autoimmune Lymphoproliferative Syndrome (ALPS). Two Case Reports.
Cayrol J; Garrido Colino C
J Pediatr Hematol Oncol; 2017 May; 39(4):e187-e190. PubMed ID: 28234735
[TBL] [Abstract][Full Text] [Related]
11. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia.
Aspinall AI; Pinto A; Auer IA; Bridges P; Luider J; Dimnik L; Patel KD; Jorgenson K; Woodman RC
Blood Cells Mol Dis; 1999; 25(3-4):227-38. PubMed ID: 10575548
[TBL] [Abstract][Full Text] [Related]
12. Expression in transgenic mice of dominant interfering Fas mutations: a model for human autoimmune lymphoproliferative syndrome.
Choi Y; Ramnath VR; Eaton AS; Chen A; Simon-Stoos KL; Kleiner DE; Erikson J; Puck JM
Clin Immunol; 1999 Oct; 93(1):34-45. PubMed ID: 10497009
[TBL] [Abstract][Full Text] [Related]
13. Reversible monoclonal lymphadenopathy in autoimmune lymphoproliferative syndrome with functional FAS (CD95/APO-1) deficiency.
Ströbel P; Nanan R; Gattenlöhner S; Müller-Deubert S; Müller-Hermelink HK; Kreth HW; Marx A
Am J Surg Pathol; 1999 Jul; 23(7):829-37. PubMed ID: 10403307
[TBL] [Abstract][Full Text] [Related]
14. Autoimmune lymphoproliferative syndrome: A disorder of immune dysregulation.
Paskiewicz A; Niu J; Chang C
Autoimmun Rev; 2023 Nov; 22(11):103442. PubMed ID: 37683818
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune lymphoproliferative syndrome, a disorder of apoptosis.
Jackson CE; Puck JM
Curr Opin Pediatr; 1999 Dec; 11(6):521-7. PubMed ID: 10590910
[TBL] [Abstract][Full Text] [Related]
16. New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome.
Teachey DT
Curr Opin Pediatr; 2012 Feb; 24(1):1-8. PubMed ID: 22157362
[TBL] [Abstract][Full Text] [Related]
17. Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children.
George LA; Teachey DT
Paediatr Drugs; 2016 Aug; 18(4):261-72. PubMed ID: 27139496
[TBL] [Abstract][Full Text] [Related]
18. Characteristic T helper 2 T cell cytokine abnormalities in autoimmune lymphoproliferative syndrome, a syndrome marked by defective apoptosis and humoral autoimmunity.
Fuss IJ; Strober W; Dale JK; Fritz S; Pearlstein GR; Puck JM; Lenardo MJ; Straus SE
J Immunol; 1997 Feb; 158(4):1912-8. PubMed ID: 9029133
[TBL] [Abstract][Full Text] [Related]
19. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome.
Straus SE; Sneller M; Lenardo MJ; Puck JM; Strober W
Ann Intern Med; 1999 Apr; 130(7):591-601. PubMed ID: 10189330
[TBL] [Abstract][Full Text] [Related]
20. The autoimmune lymphoproliferative syndrome (Canale-Smith) in adulthood.
Deutsch M; Tsopanou E; Dourakis SP
Clin Rheumatol; 2004 Feb; 23(1):43-4. PubMed ID: 14749982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
